Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Upcoming Investor Events

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in...
August 08, 2022 16:05 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force New Data...
August 01, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
July 11, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
June 01, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
May 10, 2022 06:30 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo...
May 03, 2022 16:05 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
March 28, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting

BOSTON, March 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented two posters highlighting nonclinical data...
February 28, 2022 16:05 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022 Initiating Phase 2...
February 22, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...